The use of the drug Kvamatel - comparison with analogues. Instructions for use How can I replace Kvamatel injections

In this article, you can read the instructions for using the drug Kvamatel. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Kvamatel in their practice are presented. We kindly ask you to actively add your reviews about the drug: the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Analogues of Kvamatel in the presence of existing structural analogues. Use for the treatment of gastric and duodenal ulcers and gastritis in adults, children, as well as during pregnancy and lactation.

Kvamatel- blocker of histamine H2 receptors. Reduces basal and stimulated by gastrin, pentagastrin, betazol, caffeine, histamine, acetylcholine and physiological vagal reflex secretion of hydrochloric acid. This increases the pH and decreases the activity of pepsin. Virtually no effect on gastrin levels on an empty stomach and after a meal. Does not affect gastric motility, exocrine activity of the pancreas, blood circulation in the portal system, hormone levels, does not have an antiandrogenic effect.

Famotidine (the active substance of the drug Kvamatel) has little effect on microsomal liver enzymes.

After taking the drug inside, the effect occurs after 1 hour, the maximum effect is 3 hours after administration, the duration of the effect varies between 12-24 hours, depending on the dose.

After intravenous administration, the maximum effect occurs within the first 30 minutes. The drug in the form of a lyophilisate for the preparation of a solution for intravenous administration after administration in a single dose of 20 or 40 mg in the evening suppresses basal and nocturnal secretion for 10-12 hours.

Compound

Famotidine + excipients.

Pharmacokinetics

After oral administration, it is not completely absorbed from the gastrointestinal tract. Bioavailability - 40-45%, increases with the simultaneous intake of food and decreases with the simultaneous administration of antacids. Plasma protein binding is 10-20%. Penetrates through the placental barrier and through the blood-brain barrier (BBB). It is allocated with breast milk. 30-35% of the drug is metabolized in the liver with the formation of S-oxide. After oral administration, 30-35% of famotidine, and after intravenous administration, 65-70% of famotidine is excreted in the urine unchanged.

Indications

• peptic ulcer of the duodenum and stomach in the acute phase, prevention of relapses;
• treatment and prevention of symptomatic gastric and duodenal ulcers (associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), stress, postoperative ulcers);
• erosive gastroduodenitis;
• functional dyspepsia associated with increased secretory function of the stomach;
• reflux esophagitis;
• Zollinger-Ellison syndrome;
• prevention of recurrence of bleeding from the upper gastrointestinal tract;
• prevention of aspiration of gastric juice during general anesthesia (Mendelssohn's syndrome);
• symptomatic treatment of dyspepsia associated with increased acidity of gastric juice (heartburn, sour belching, etc.) (Kvamatel mini).

Release form

Film-coated tablets 10 mg (Kvamatel mini), 20 mg and 40 mg.

Lyophilizate for the preparation of a solution for intravenous administration (injections in ampoules for injection).

Instructions for use and dosing regimen

Pills

With peptic ulcer of the stomach and duodenum in the acute phase, Kvamatel is prescribed at a dose of 40 mg 1 time per day at bedtime or 20 mg 2 times a day, morning and evening. If necessary, the daily dose can be increased to 80-160 mg. The duration of the course of treatment is on average 4-8 weeks.

In order to prevent exacerbations of peptic ulcer of the stomach and duodenum, Kvamatel is prescribed at a dose of 20 mg 1 time per day at bedtime.

With reflux esophagitis, the drug is prescribed at a dose of 20 mg 2 times a day (morning and evening) for 6 weeks; if necessary - 40 mg 2 times a day.

With Zollinger-Ellison syndrome, the initial dose is 20-40 mg every 6 hours; if necessary, the daily dose can be increased to 240-480 mg. The duration of the drug depends on the clinical condition of the patient.

In order to prevent aspiration of gastric contents during general anesthesia, Kvamatel is prescribed at a dose of 40 mg on the eve of surgery and / or in the morning on the day of surgery.

Kvamatel mini

In case of heartburn or other symptoms of dyspepsia, take 1 tablet. The tablet should be swallowed whole with a small amount of water. Do not use more than 2 tablets per day. If the symptoms do not go away within 2 weeks of using the drug, you should consult a doctor.

Ampoules

Kvamatel is used intravenously, by stream or drip (dropper) only in severe cases or when it is impossible to take the drug inside.

Intended for hospital use only. Switch to oral famotidine as soon as possible. The average dose is 20 mg 2 times a day (every 12 hours). A single dose should not exceed 20 mg.

With Zollinger-Ellison syndrome, the initial dose is 20 mg every 6 hours, further the dose of the drug is adjusted depending on the secretion of hydrochloric acid and on the clinical condition of the patient.

To prevent aspiration of gastric contents, before general anesthesia, 20 mg of the drug is administered intravenously on the eve of the operation or at least 2 hours before the start of the operation.

In patients with impaired renal function (CC less than 30 ml / min), or with a serum creatinine level of more than 3 mg / dl, the daily dose of the drug (both for oral administration and for intravenous administration) is reduced to 20 mg or the interval is increased between the use of individual doses of the drug up to 36-48 hours.

In case of impaired liver function, the drug is prescribed with caution, in reduced doses.

Rules for the preparation and administration of solutions for injection

To prepare the solution, the contents of one ampoule with the active substance must first be diluted in 5-10 ml of saline (solvent ampoule). The prepared solution remains stable at room temperature for 24 hours. The drug is administered for at least 2 minutes. With intravenous drip, the duration of the infusion should be 15-30 minutes. The shelf life of an infusion solution prepared using a dextrose solution with potassium chloride or sodium lactate is 4 hours; using isodex - 5 hours, Ringer's solutions, Ringer-lactate or salsol A - 8 hours. The solution should be prepared immediately before administration.

Side effect

• dry mouth;
• nausea, vomiting;
• stomach ache;
• flatulence;
• constipation;
• diarrhea;
• loss of appetite;
• acute pancreatitis;
• agranulocytosis, pancytopenia, leukopenia, thrombocytopenia;
• hives;
• skin rash;
• bronchospasm;
• angioedema;
• anaphylactic shock;
• arrhythmia;
• bradycardia;
• AV block;
• decrease in blood pressure;
• headache;
• dizziness;
• drowsiness;
• hallucinations;
• confusion;
• increased fatigue;
• decreased visual acuity;
• noise in ears;
• hyperprolactinemia;
• gynecomastia;
• amenorrhea;
• decreased libido;
• myalgia;
• arthralgia;
• alopecia;
• acne vulgaris;
• dry skin;
• fever.

Contraindications

• pregnancy;
• lactation period (breastfeeding);
• childhood;
• hypersensitivity to the components of the drug;
• hypersensitivity to other blockers of histamine H2 receptors.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy. If necessary, the use of the drug breastfeeding should be discontinued.

special instructions

The use of Kvamatel can mask the symptoms of stomach cancer, therefore, before starting treatment with famotidine, it is necessary to exclude the presence of a malignant neoplasm.

With a sharp cessation of treatment, famotidine can cause a withdrawal syndrome, so treatment is stopped, gradually reducing its dose.

In patients with impaired liver function, Kvamatel should be administered with caution and at lower doses.

With long-term treatment of debilitated patients or patients under stress, bacterial lesions of the stomach are possible with further spread of infection.

Kvamatel should be taken 2 hours after taking itraconazole or ketoconazole in order to avoid a significant decrease in their absorption. You should also observe a 1-2 hour break between taking Kvamatel and antacids.

Blockers of histamine H2 receptors (including Kvamatel) can inhibit the acid-stimulating effect of pentagastrin and histamine, so Kvamatel should be discontinued 24 hours before the test.

Histamine H2 receptor blockers can suppress the skin reaction to histamine, thus leading to false negative results. Therefore, before conducting diagnostic skin tests to detect an allergic skin reaction of the immediate type, Kvamatel should be canceled.

During treatment, you should avoid eating foods, drinks (including alcohol) and other drugs that can cause irritation of the gastric mucosa.

Influence on the ability to drive vehicles and control mechanisms

During the period of taking Kvamatel, patients should be careful when driving vehicles and engaging in potentially hazardous activities that require increased concentration and psychomotor speed.

drug interaction

Due to an increase in the pH of the contents of the stomach, Kvamatel, with simultaneous use, reduces the absorption of ketoconazole and itraconazole; increases the absorption of amoxicillin and clavulanic acid.

Antacids and sucralfate, used simultaneously with Kvamatel, slow down the absorption of famotidine.

• high bioavailability of the drug;
• rapid accumulation in the body at maximum concentration;
• delayed half-life of the drug from the body;
• the presence of several forms of release of the drug: lyophilizate for the preparation of a solution for intravenous administration of 20 mg in a vial, film-coated tablets of 20 mg and 40 mg.

Flaws:

• high price of the drug compared to analogues.

• Lyophilisate for solution for intravenous administration 20 mg, 72.8 mg vial with solvent in ampoules and ampoule knife, cardboard pack 5

  387 rub.

• Film-coated tablets 40 mg, blister 14, carton pack 1

  125 rub.

• Film-coated tablets 20 mg, blister 14, carton pack 2

  140 rub.

* The maximum permissible retail price of medicines is indicated, calculated in accordance with Decree of the Government of the Russian Federation No. 865 dated October 29, 2010 (For those medicines that are on the list)

Instructions for use:

The lyophilizate in the vial is diluted with saline and administered intravenously in a stool (when diluted with 10-15 ml of saline) or drip (when diluted with 150-200 ml of saline).

This form of release is prescribed to patients who are being treated in a hospital and is used for Zollinger-Ellison syndrome, bleeding from the upper gastrointestinal tract, in the active phase of gastric ulcer and / or duodenal ulcer.

The drug is prescribed 20 mg 1-2 times a day, depending on the severity of the condition. The maximum daily dose of this form of release of the drug should not exceed 80 mg.

Tablets are taken orally, 30 minutes before a meal or 1.5-2 hours after a meal, with a small amount of water 1-2 times a day.

For the treatment of GERD, gastritis and erosive gastroduodenitis, the drug is prescribed 20-40 mg 1-2 times a day. The maximum daily dose is 120 mg.

For the treatment of peptic ulcer of the stomach and duodenum, the drug is prescribed 40 mg 1 time per day at night or 20 mg 2 times a day (morning and evening). The maximum daily dose of the drug for this disease is 120-140 mg.

For the treatment of Zollinger-Ellison syndrome, the drug is prescribed 40 mg every 5-6 hours (4 times a day). The maximum daily dose of the drug is 240-480 mg.

To prevent bleeding from the upper gastrointestinal tract, the drug is prescribed 20 mg 1 time per day at night.

For the treatment of systemic mastocytosis and polyendocrine adenomatosis, the drug is prescribed 80 mg 3 times a day. The maximum daily dose of the drug for these diseases is 480 mg.

For the prevention of Mendelssohn's syndrome, the drug is prescribed 40 mg 1 day before surgery or, directly in the morning, on the day of surgery.

The duration of treatment is individual and is decided in each case by the attending physician.

Patients who suffer from chronic renal failure, with a sharp violation of the function of the organ, the drug is prescribed with caution in a dose not exceeding 20 mg 1 time per day.

During pregnancy and lactation, the drug is not prescribed.

Children under 18 years of age are prohibited from prescribing the drug.

comparison table

Name of the drug	Bioavailability, %	Bioavailability, mg/l	Time to reach maximum concentration, h	Half-life, h
Kvamatel

INSTRUCTIONS

on the use of funds

Kvamatel

Release form

Tablets, ampoules, powders

Pharmacological properties

Famotidine is a powerful competitive inhibitor of H2-histamine receptors. The main clinically significant pharmacological action of famotidine is the inhibition of gastric secretion. Famotidine reduces both the concentration of acid and the volume of gastric secretion, while the production of pepsin remains proportional to the volume of secreted gastric juice.

Both in healthy volunteers and in patients with hypersecretion, famotidine inhibits both basal and nocturnal secretion and secretion stimulated by pentagastrin, betazol, caffeine, insulin, or the physiological vagal reflex.

The duration of secretion inhibition when using doses of 20 and 40 mg is 10-12 hours.

A single oral dose of 20 and 40 mg in the evening provides inhibition of basal and nocturnal secretion of hydrochloric acid.

Famotidine has little or no effect on fasting or postprandial gastrin levels.

Famotidine has no effect on gastric emptying, exocrine pancreatic function, blood flow in the liver and portal system.

Famotidine does not affect the liver cytochrome P450 enzyme system.

No antiandrogenic effect of the drug was noted. The level of plasma hormones after treatment with famotidine did not change.

Indications

Benign stomach ulcer. Duodenal ulcer. Hypersecretion states, Zollinger-Ellison syndrome. Treatment of gastroesophageal reflux disease. Prevention of aspiration of acidic gastric contents (Mendelssohn's syndrome) during general anesthesia.

Contraindications

Hypersensitivity to any component of the drug and other H2-histamine receptor antagonists; children's age, pregnancy and lactation (due to lack of necessary clinical experience).

Use during pregnancy and lactation

Kvamatel is contraindicated in women at the stage of pregnancy and lactation.

Compound

1 vial of Kvamatel in the form of a lyophilized powder for injection contains:

Famotidine - 20 mg;

Excipients.

1 ampoule with solvent contains:

Sodium chloride solution 0.9% - 5 ml;

1 film-coated tablet of Kvamatel 20 contains:

Famotidine - 20 mg;

1 film-coated tablet of Kvamatel 40 contains:

Famotidine - 40 mg;

Excipients, including lactose monohydrate.

1 film-coated tablet of Kvamatel Mini contains:

Famotidine - 10 mg;

Excipients, including lactose monohydrate.

Dosage and administration

Kvamatel tablets are intended for oral administration. The dosage and duration of treatment is selected by the doctor individually, taking into account clinical indicators. When treating duodenal ulcers and stomach ulcers, the drug is taken 40 mg once a day and preferably in the evening, or 20 mg twice a day. If necessary, the dose of the drug can be increased to 160 mg. The duration of treatment can vary from 4 to 8 weeks.

To prevent the development of exacerbation of gastric ulcer, the drug should be taken at a dose of 20 mg once a day. In the treatment of reflux esophagitis, 20 mg of the drug should be taken 2 times a day for 6 weeks, if the desired therapeutic effect cannot be achieved in the starting dose, then the dose of the drug can be increased to 80 mg.

The lyophilizate for the preparation of the solution is intended for intravenous drip or jet administration only in a hospital setting. The drug is used to treat severe forms of the disease or when it is impossible to take Kvamatel in oral form. Before administration, the contents of the vial are diluted in 5 or 10 ml of solvent.

Side effects

Treatment with Kvamatel may be accompanied by the development of nausea, vomiting, decreased appetite, impaired stools, flatulence, dryness of the oral mucosa, emotional lability, increased anxiety, hallucinations, heart rhythm disturbances, dizziness, fever and muscle pain.

Interaction with other drugs

Absorption of certain drugs (eg, ketoconazole, amoxicillin, iron preparations) depends on the acidity of the gastric juice. Therefore, famotidine must be used at least 2 hours after taking such drugs.

Simultaneous use with other H2 receptor antagonists can significantly reduce the effectiveness of tolazoline. Although there are no confirmed interactions between famotidine and tolazoline, the likelihood of their existence is high enough that the effect of tolazoline should be determined at the beginning and after completion of concomitant treatment. In the event of a decrease in the effect of tolazoline, the dose should be gradually increased or treatment with famotidine should be discontinued.

Food and antacids do not significantly affect famotidine treatment.

Famotidine does not affect the hepatic cytochrome P450 oxidase system, so the metabolism of oral anticoagulants, antipyrine, aminopyrine, theophylline, phenytoin, diazepam, ethanol and propranolol remains unchanged.

Probenecid may slow down the release of famotidine.

Overdose

When using famotidine during the year at a dose of 800 mg / day in patients with hypersecretion of gastric juice, no severe side effects were detected.

Symptoms: vomiting, motor excitation, tremor, decrease in blood pressure, tachycardia, ventricular arrhythmia and collapse may develop.

Treatment: symptomatic and supportive therapy is used if necessary - in / in the introduction of diazepam in case of seizures, atropine in case of bradycardia and lidocaine in case of ventricular arrhythmia. Hemodialysis is effective. Monitoring the patient's condition.

Storage conditions

Best before date

The most frequent complications of the digestive tract encountered in the practice of a gastroenterologist are erosive and ulcerative lesions of the mucosa of the gastrointestinal tract and associated internal bleeding. The frantic rhythm of life is the source of a mass of all kinds of stressful factors, which, in turn, stimulate the release of corticosteroids, adrenocorticotropic hormone, histamine, catecholamines. This biochemical cocktail in excess does not do anything good, stimulating the hypersecretion of hydrochloric acid and pepsin, shifting the pH to the acid side and reducing the protective potential of the gastric mucosa. In such cases, the need to prevent such situations comes to the fore, where drug therapy with drugs that reduce the acidity of the stomach acts as its main means. Being a blocker of histamine receptors of the third generation, the original drug kvamatel (INN - famotidine) from the Hungarian pharmaceutical plant "Gedeon Richter" rightfully occupies one of the prominent places in the list of antiulcer drugs.

The main therapeutically significant pharmacological effect of Kvamatel is the suppression of gastric juice secretion both in quantitative (secretion volume) and qualitative (hydrochloric acid concentration) terms. In addition, the drug strengthens the "protective bastions" of the gastric mucosa by activating blood flow in it, increasing the production of bicarbonate salts, and activating the restoration of the epithelium.

The popularity of Kvamatel among specialists and patients is associated with the absence of a number of shortcomings in the drug that its predecessors have, plus the presence in its “personal file” of several undeniable advantages actively announced by the manufacturer. So, the effective dose of this drug - 40 mg - is much less than that of ranitidine and cimetidine. and the duration of action is longer (10-12 hours versus 7-8 hours for ranitidine and 5-6 hours for cimetidine). Among other positive qualities of Kvamatel is the minimum number of side effects, the probability of which does not exceed 1%. The drug does not interfere with the functioning of the liver and male gonads, does not cause gynecomastia, does not increase the bioavailability of alcoholic beverages (therefore, it can be used in people who abuse alcohol).

Kvamatel is available in two dosage forms: tablets and lyophilisate for the preparation of a solution for intravenous (only intravenous!) administration. The presence of an injectable form can also be written into the benefits of kvamatel. The drug quickly relieves pain in acute attacks of gastric ulcer and 12 duodenal ulcer. With oral administration of Kvamatel at a daily dose of 40 mg, pain is relieved within 7 days in 66% of patients. With an injection of 20 mg 2 times a day, the disappearance of the pain syndrome can be expected as early as 3-4 days of therapy.

An important condition for the appointment of kvamatel is a preliminary study of the digestive tract for the absence of malignant neoplasms.

Pharmacology

Blocker of histamine H 2 receptors. Reduces basal and stimulated by gastrin, pentagastrin, betazol, caffeine, histamine, acetylcholine and physiological vagal reflex secretion of hydrochloric acid. This increases the pH and decreases the activity of pepsin. Virtually no effect on gastrin levels on an empty stomach and after a meal. Does not affect gastric motility, exocrine activity of the pancreas, blood circulation in the portal system, hormone levels, does not have an antiandrogenic effect.

Famotidine has little effect on microsomal liver enzymes.

After taking the drug inside, the effect occurs after 1 hour, the maximum effect is 3 hours after administration, the duration of the effect varies between 12-24 hours, depending on the dose.

The drug in the form of a lyophilisate for the preparation of a solution for intravenous administration after administration in a single dose of 20 or 40 mg in the evening suppresses basal and nocturnal secretion for 10-12 hours.

Pharmacokinetics

Pharmacokinetics is linear.

Suction

After oral administration, it is not completely absorbed from the gastrointestinal tract. C max is reached in 1-3 hours and is 0.07-0.1 mg/l. Bioavailability - 40-45%, increases with the simultaneous intake of food and decreases with the simultaneous administration of antacids.

Distribution

Plasma protein binding is 10-20%. Penetrates through the placental barrier and through the BBB. It is allocated with breast milk.

Metabolism

30-35% of the drug is metabolized in the liver with the formation of S-oxide.

breeding

T1 / 2 is 2.3-3.5 hours. After oral administration of 30-35% famotidine, and after intravenous administration, 65-70% of famotidine is excreted in the urine unchanged.

Pharmacokinetics in special clinical situations

With QC<10 мл/мин T 1/2 может достигать 20 ч.

Release form

Pink film-coated tablets, convex, debossed "F20" on one side; on a break of white or almost white color.

	1 tab.
famotidine	20 mg

Excipients: colloidal silicon dioxide, magnesium stearate, povidone K90, sodium carboxymethyl starch (type A), talc, corn starch, lactose monohydrate.

Shell composition: red iron oxide, colloidal silicon dioxide, titanium dioxide, macrogol 6000, sepifilm 003 (macrogol-40 OE stearate (E431), microcrystalline cellulose (E460), hypromellose (E464)).

14 pcs. - blisters (2) - cardboard boxes.

Dosage

For oral administration

In case of peptic ulcer of the stomach and duodenum in the acute phase, Kvamatel® is prescribed at a dose of 40 mg 1 time / day at bedtime or 20 mg 2 times / day, morning and evening. If necessary, the daily dose can be increased to 80-160 mg. The duration of the course of treatment is on average 4-8 weeks.

In order to prevent exacerbations of peptic ulcer of the stomach and duodenum, Kvamatel ® is prescribed at a dose of 20 mg 1 time / day at bedtime.

With reflux esophagitis, the drug is prescribed at a dose of 20 mg 2 times / day (morning and evening) for 6 weeks; if necessary - 40 mg 2 times / day.

With Zollinger-Ellison syndrome, the initial dose is 20-40 mg every 6 hours; if necessary, the daily dose can be increased to 240-480 mg. The duration of the drug depends on the clinical condition of the patient.

In order to prevent aspiration of gastric contents during general anesthesia, Kvamatel ® is prescribed at a dose of 40 mg on the eve of surgery and / or in the morning on the day of surgery.

For intravenous administration

Kvamatel ® is used in/in, jet or drip only in severe cases or when it is impossible to take the drug inside.

Intended for hospital use only. Switch to oral famotidine as soon as possible. The average dose is 20 mg 2 times / day (every 12 hours). A single dose should not exceed 20 mg.

With Zollinger-Ellison syndrome, the initial dose is 20 mg every 6 hours, further the dose of the drug is adjusted depending on the secretion of hydrochloric acid and on the clinical condition of the patient.

To prevent aspiration of gastric contents, before general anesthesia, 20 mg of the drug is administered intravenously on the eve of the operation or at least 2 hours before the start of the operation.

In patients with impaired renal function (CC less than 30 ml / min), or with a serum creatinine level of more than 3 mg / dl, the daily dose of the drug (both for oral administration and for intravenous administration) is reduced to 20 mg or the interval is increased between the use of individual doses of the drug up to 36-48 hours.

Rules for the preparation and administration of solutions for injection

To prepare the solution, the contents of one ampoule with the active substance must first be diluted in 5-10 ml of saline (solvent ampoule). The prepared solution remains stable at room temperature for 24 hours. The drug is administered for at least 2 minutes. With intravenous drip, the duration of the infusion should be 15-30 minutes. The solution should be prepared immediately before administration.

Overdose

Symptoms: vomiting, motor excitation, tremor, decrease in blood pressure, tachycardia, collapse.

Treatment: gastric lavage, symptomatic and supportive therapy; hemodialysis.

Interaction

Due to the increase in the pH of the contents of the stomach, Kvamatel ®, with simultaneous use, reduces the absorption of ketoconazole and itraconazole; increases the absorption of amoxicillin and clavulanic acid.

Antacids and sucralfate, used simultaneously with Kvamatel, slow down the absorption of famotidine.

With the simultaneous administration of Kvamatel and drugs that inhibit bone marrow hematopoiesis, the risk of developing neutropenia increases.

Side effects

From the digestive system: dry mouth, nausea, vomiting, abdominal pain, flatulence, constipation, diarrhea, loss of appetite; increased activity of liver transaminases, hepatocellular, cholestatic or mixed hepatitis, acute pancreatitis.

On the part of the hematopoietic system: very rarely - agranulocytosis, pancytopenia, leukopenia, thrombocytopenia, hypo- or aplasia of the bone marrow.

Allergic reactions: urticaria, skin rash, itching, bronchospasm, angioedema, anaphylactic shock.

From the side of the cardiovascular system: arrhythmia, bradycardia, AV blockade, lowering blood pressure.

From the side of the central nervous system: headache, dizziness, drowsiness, hallucinations, confusion, fatigue, depression, agitation, anxiety.

From the senses: decreased visual acuity, tinnitus.

From the reproductive system: with prolonged use in high doses - hyperprolactinemia, gynecomastia, amenorrhea, decreased libido.

From the musculoskeletal system: arthralgia, muscle spasms.

Dermatological reactions: alopecia, acne vulgaris, dry skin, toxic epidermal necrolysis.

Other: fever.

Indications

• peptic ulcer of the duodenum and stomach in the acute phase, prevention of relapses;
• treatment and prevention of symptomatic gastric and duodenal ulcers (associated with taking NSAIDs, stress, postoperative ulcers);
• erosive gastroduodenitis;
• functional dyspepsia associated with increased secretory function of the stomach;
• reflux esophagitis;
• Zollinger-Ellison syndrome;
• prevention of recurrence of bleeding from the upper gastrointestinal tract;
• prevention of aspiration of gastric juice during general anesthesia (Mendelssohn's syndrome).

Contraindications

• pregnancy;
• lactation period (breastfeeding);
• childhood;
• hypersensitivity to the components of the drug;
• hypersensitivity to other blockers of histamine H 2 receptors.

With caution, the drug should be prescribed for renal and hepatic insufficiency, with cirrhosis of the liver with a history of portosystemic encephalopathy.

Application features

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy. If necessary, the use of the drug during lactation, breastfeeding should be discontinued.

Application for violations of liver function

In case of impaired liver function, the drug is prescribed with caution, in reduced doses.

Application for violations of kidney function

For patients with impaired renal function (CC less than 30 ml / min), or with a serum creatinine level of more than 3 mg / dl, the daily dose of the drug (both for oral administration and for intravenous administration) is reduced to 20 mg or the interval is increased between the use of individual doses of the drug up to 36-48 hours.

special instructions

The use of Kvamatel can mask the symptoms of stomach cancer, therefore, before starting treatment with famotidine, it is necessary to exclude the presence of a malignant neoplasm.

With a sharp cessation of treatment, famotidine can cause a withdrawal syndrome, so treatment is stopped, gradually reducing its dose.

Patients with impaired liver function Kvamatel ® should be prescribed with caution and at lower doses.

With long-term treatment of debilitated patients or patients under stress, bacterial lesions of the stomach are possible with further spread of infection.

Kvamatel ® should be taken 2 hours after taking itraconazole or ketoconazole in order to avoid a significant decrease in their absorption. You should also observe a 1-2 hour break between taking Kvamatel and antacids.

Blockers of histamine H 2 receptors (including Kvamatel ®) can inhibit the acid-stimulating effect of pentagastrin and histamine, therefore, Kvamatel should be discontinued 24 hours before the test.

Histamine H 2 receptor blockers can suppress the skin reaction to histamine, thus leading to false negative results. Therefore, before carrying out diagnostic skin tests to detect an allergic skin reaction of the immediate type, Kvamatel ® should be canceled.

During treatment, you should avoid eating foods, drinks and other drugs that can cause irritation of the gastric mucosa.

Influence on the ability to drive vehicles and control mechanisms

During the period of taking the drug Kvamatel ®, patients should be careful when driving vehicles and engaging in potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Total analogues: 21. Price and availability of Kvamatel analogues in pharmacies. Before using any medication, you should definitely consult your doctor.

This page provides a list analogues of Kvamatel- these are interchangeable drugs that have similar indications for use and belong to the same pharmacological group. Before you buy analog Kvamatel, it is necessary to consult with a specialist regarding the replacement of the drug, study in detail, read and a similar drug.

• Tykveol

  A drug Tykveol intended for oral administration: cirrhosis of the liver, chronic hepatitis, fatty degeneration of the liver, infectious hepatitis, toxic liver damage (drugs, industrial poisons, alcohol), cholecystitis (non-calculous), cholestasis, biliary dyskinesia, gastritis, colitis, enterocolitis (non-infectious origin) ), hemorrhoids, atherosclerosis, prostatitis, benign prostatic hyperplasia,
  For rectal use: chronic prostatitis, benign prostatic hyperplasia stage I-II with concomitant prostatitis.
  For external and local use: herpes, dermatitis, psoriasis, eczema, burns and burn disease, cervical erosion, colpitis, endocervicitis, periodontal disease.

• Ulcavis

  Ulcavis are:
  
  
  - Irritable bowel syndrome, which occurs mainly with symptoms of diarrhea.
  

• Norvela

  Indications for the use of the drug Norvela are:
  - treatment of damage to the gastric mucosa (erosion, hemorrhage, hyperemia, edema) in acute and chronic gastritis
  - prevention of gastropathy caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs)

• Lantorol

  Indications for the use of the drug Lantorol are:
  - peptic ulcer of the stomach and duodenum;
  - erosive and ulcerative lesions of the stomach and duodenum associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), stress ulcers;
  - gastroesophageal reflux disease (GERD): treatment of reflux esophagitis, symptomatic treatment of reflux esophagitis;
  - eradication of Helicobacter pylori (in combination with antibiotics);
  - pathological hypersecretory conditions, including Zollinger-Ellison syndrome;
  - chronic gastritis with increased acid-forming function of the stomach in the acute stage;
  - non-ulcer dyspepsia.
  

• PILERA

• Rabeprazole

  Indications for the use of the drug Rabeprazole are: active peptic ulcer of the duodenum; active benign gastric ulcer; erosive or ulcerative gastroesophageal reflux disease (GERD); long-term treatment of gastroesophageal reflux disease (maintenance therapy for GERD); symptomatic treatment of moderate to very severe gastroesophageal reflux disease (symptomatic treatment of GERD); Zollinger-Ellison syndrome; in combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori (H. pylori) in patients with peptic ulcers of the stomach and duodenum.
  

• Escape

  A drug Escape recommended for use:
  - with exacerbation of chronic gastritis, gastroduodenitis, gastric and duodenal ulcers, not associated with Helicobacter pylori;
  - for the treatment of gastritis and peptic ulcer of the stomach and duodenum in the acute phase caused by Helicobacter pylori;
  - with functional dyspepsia (heartburn, abdominal discomfort and bloating) not associated with organic diseases of the gastrointestinal tract;
  - with irritable bowel syndrome.

• Omeprazole

  adults Omeprazole taken for the following diseases:
  - Peptic ulcer of the stomach and duodenum (in the acute phase and anti-relapse treatment), incl. caused by Helicobacter pylori (as part of combination therapy);
  - Gastroesophageal reflux disease, reflux esophagitis, incl. erosive (in the acute phase and anti-relapse treatment);
  - Hypersecretory conditions (Zollinger-Ellison syndrome, stress ulcers of the gastrointestinal tract, polyendocrine adenomatosis, systemic mastocytosis);
  - Erosive and ulcerative lesions of the stomach and duodenum caused by the intake of non-steroidal anti-inflammatory drugs (NSAIDs).
  In children, the drug Omeprazole used in the treatment of such diseases:
  - Gastroesophageal reflux disease in children older than 2 years.
  - Peptic ulcer of the duodenum caused by Helicobacter pylori (as part of combination therapy) in children older than 4 years.
  

• Omeprazole-Acre

  Indications for the use of the drug Omeprazole-Acre are:
  - peptic ulcer of the stomach and duodenum (including prevention of relapse);
  - reflux esophagitis;
  
  - stress ulcers of the gastrointestinal tract (GIT);
  - polyendocrine adenomatosis;
  - systemic mastocytosis;
  - gastropathy caused by the use of non-steroidal anti-inflammatory drugs (NSAID-gastropathy);
  - eradication of Helicobacter pylori in infected patients with gastric ulcer and duodenal ulcer (as part of combination therapy).
  

• Ontime

  Indications for the use of the drug Ontime are:
  - peptic ulcer of the stomach and duodenum in the acute phase;
  - erosive or ulcerative gastroesophageal reflux disease (GERD);
  - long-term maintenance therapy for GERD;
  - symptomatic treatment of GERD;
  - Zollinger-Ellison syndrome;
  - eradication of Helicobacter pylori in combination with antibacterial agents.
  

• Novobismol

  Indications for the use of the drug Novobismol are:
  - Peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori.
  - Chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori.
  - Functional dyspepsia, not associated with organic diseases of the gastrointestinal tract.
  

• Ulsepan tablets

  Indications for the use of the drug Ulsepan are:
  - peptic ulcer of the stomach or duodenum
  - reflux esophagitis
  - pathological hypersecretory conditions, including Zollinger-Ellison syndrome
  - eradication of Helicobacter pylori (in combination with antibiotic therapy)
  

• Ulsepan

  Indications for the use of the drug Ulsepan are:
  - reflux esophagitis of moderate and severe degree;
  - eradication of Helicobacter pylori in patients with peptic ulcer caused by this microorganism, in combination with certain antibiotics;
  - gastric and duodenal ulcer;
  - Zollinger-Ellison syndrome and other pathological hypersecretory conditions.
  

• Glustab

  Taking the drug Glustab recommended for diabetes mellitus - regular intake contributes to the normalization of blood sugar, in patients with diabetes, there is a slowdown in the development of diabetic nephropathy, retinopathy, damage to the vessels of the extremities;
  With atherosclerosis, coronary heart disease, overweight - significantly reduces the level of cholesterol and triglycerides in the blood, which prevents the further development of vascular atherosclerosis;
  In diseases of the gastrointestinal tract - it has an anti-inflammatory and regenerating effect in gastric and duodenal ulcers, gastritis; is an effective means of detoxifying the body and restoring the intestinal microflora in case of malnutrition, antibiotic treatment;
  In case of poisoning with organic solvents, including alcohol, poisoning with heavy metals (lead, zinc, cobalt, nickel), radionuclides (strontium-90, cesium-137) - neutralizes the pathogenic effect of aggressive free radicals and underoxidized metabolic products, while in the intestinal lumen a physiological alkaline reaction is established, which is necessary for the normal enzymatic digestion of food. With a decrease in immunity, frequent SARS, influenza, colds, chronic fatigue syndrome, for the prevention of neoplasms in adverse environmental conditions, etc.
  

• Anacid

  Capsules Anacid recommended as a biologically active food supplement - contributing to the improvement of the functional state of the digestive system.
  Diseases for which it is recommended to take the drug:
  - Heartburn and sour belching in adults and children over 10 years of age
  - Peptic ulcer of the stomach and duodenum in the acute phase
  - Acute gastroduodenitis
  - Chronic gastroduodenitis with normal or increased function in the acute phase
  - Reflux esophagitis
  - The phenomena of dyspepsia (and their prevention), resulting from the use of certain drugs
  - Discomfort: flatulence, nausea, vomiting, epigastric pain
  

• Simalgel

• Losek Maps

  Losek Maps is intended for the treatment of the following diseases:
  - duodenal ulcer
  - stomach ulcer
  - NSAID-associated ulcers and erosions of the stomach and duodenum
  - eradication of Helicobacter pylori in peptic ulcer disease
  - reflux esophagitis
  - symptomatic gastroesophageal reflux disease
  - dyspepsia associated with hyperacidity
  - Zollinger-Ellison syndrome
  

• Fametol

  Fametol is indicated for the short-term symptomatic treatment of conditions due to hyperacidity of the gastric juice (heartburn, pain, heaviness, bloating, flatulence, nausea, sour belching) caused by acute and chronic gastritis, peptic ulcer of the stomach or duodenum, reflux, pylorospasm, including symptoms, caused by poor diet, medication, excessive drinking or smoking.
  Omez D are: functional dyspepsia, delayed evacuation of the contents of the stomach and gastroparesis, reflux esophagitis, peptic ulcer of the stomach and duodenum; in Helicobacter pylori eradication schemes in the presence of gastroesophageal reflux.
  

• Rabimak

  Indications for the use of the drug Rabimak are: active duodenal ulcer; active benign gastric ulcer; erosive or ulcerative gastroesophageal reflux disease (GERD); long-term treatment of gastroesophageal reflux disease (maintenance therapy for GERD); symptomatic treatment of moderate to very severe gastroesophageal reflux disease (symptomatic treatment of GERD); Zollinger-Ellison syndrome, in combination with appropriate antibacterial regimens for the eradication of Helicobacter pylori (H. pylori) in patients with gastric and duodenal ulcers.